Timothy Eugene Sullivan Sells 1,730 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CFO Timothy Eugene Sullivan sold 1,730 shares of Apellis Pharmaceuticals stock in a transaction dated Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $51,830.80. Following the completion of the sale, the chief financial officer now directly owns 86,370 shares in the company, valued at $2,587,645.20. This represents a 1.96 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Timothy Eugene Sullivan also recently made the following trade(s):

• On Monday, January 13th, Timothy Eugene Sullivan sold 2,170 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total value of $62,279.00.

Apellis Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ:APLS opened at $30.39 on Thursday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a market capitalization of $3.78 billion, a P/E ratio of -14.97 and a beta of 0.94. The business’s 50 day simple moving average is $31.95 and its 200 day simple moving average is $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period in the prior year, the business earned ($1.17) earnings per share. Apellis Pharmaceuticals’s quarterly revenue was up 78.3% compared to the same quarter last year. On average, research analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. HC Wainwright restated a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, January 14th. Robert W. Baird reduced their price target on Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Citigroup lowered their target price on shares of Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Finally, Morgan Stanley assumed coverage on shares of Apellis Pharmaceuticals in a research note on Thursday, November 21st. They set an “equal weight” rating and a $31.00 price objective on the stock. Eight equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors have recently modified their holdings of APLS. HighVista Strategies LLC grew its position in Apellis Pharmaceuticals by 4.1% in the second quarter. HighVista Strategies LLC now owns 7,566 shares of the company’s stock valued at $290,000 after acquiring an additional 300 shares during the last quarter. Amalgamated Bank grew its stake in shares of Apellis Pharmaceuticals by 5.4% during the second quarter. Amalgamated Bank now owns 6,995 shares of the company’s stock worth $268,000 after buying an additional 359 shares during the last quarter. KBC Group NV increased its holdings in shares of Apellis Pharmaceuticals by 34.8% during the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the last quarter. Finally, Wolverine Asset Management LLC acquired a new stake in shares of Apellis Pharmaceuticals during the 3rd quarter valued at $27,000. Institutional investors and hedge funds own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).